Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RH110 lyophilized zoster mRNA vaccine in healthy Chinese adults aged 40 years and older
CTR20254682Phase 2Active
- Sponsor
- Wuhan Ruiji Biotechnology
- Start
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of RH110 in herpes zoster (HZ), sponsored by Wuhan Ruiji Biotechnology. Started Nov 2025; status: active.
02
Drugs
RH110
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20254682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254682.